UseGrants

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)

National Institutes of HealthAmount not specifiedDue Jan 7, 2027
View & apply on Grants.gov →

This NIH/NHLBI R61/R33 supports investigator-initiated Phase I clinical trials for therapeutics or diagnostics for heart, lung, blood, and sleep disorders, with the first phase funding final pre-tr…

Deadline
Jan 7, 2027
Posted
Dec 5, 2024
Award amount
Amount not specified
Focus areas
Health

Don’t miss this deadline

We’ll email you before Jan 7, 2027 so you have time to apply.

In plain English

This NIH/NHLBI R61/R33 supports investigator-initiated Phase I clinical trials for therapeutics or diagnostics for heart, lung, blood, and sleep disorders, with the first phase funding final pre-trial preparation. A clinical trial is required. Eligible applicants include universities, research institutions, tribal and community organizations, and foreign organizations. It is aimed at research teams with clinical-trial capacity. No specific award amount is stated.

AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

About this grant

The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

Let AI draft your application

Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.

Application Kit — $49 one-time

Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.

Get the Application Kit

Related grants

Other open grants funding Health — soonest deadline first.

Also listed under National Institutes of Health and Health Grants.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.